vesencumab

a rodent and primate cross-binding human monoclonal antibody against Neuropilin-1 (NRP1) that exhibits inhibition of tumor growth in NPR1-expressing preclinical models

Also Known As:

MNRP-1685A; MNRP1685A

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        vesencumab: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        vesencumab: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        vesencumab: 4

Experts

1.	Brachmann, Rainer K: 3 articles (08/2014 - 09/2012)
2.	Xiang, Hong: 3 articles (08/2014 - 09/2012)
3.	Xin, Yan: 3 articles (08/2014 - 09/2012)
4.	Beeram, Muralidhar: 2 articles (08/2014 - 05/2014)
5.	Gore, Lia: 2 articles (08/2014 - 05/2014)
6.	Papadopoulos, Kyriakos P: 2 articles (08/2014 - 05/2014)
7.	Patnaik, Amita: 2 articles (08/2014 - 05/2014)
8.	Weekes, Colin D: 2 articles (08/2014 - 05/2014)
9.	Yu, Ron: 2 articles (08/2014 - 05/2014)
10.	Hegde, Priti: 1 article (08/2014)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2014 - "A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors." 08/01/2014 - "We explored the safety and tolerability of MNRP1685A in patients with advanced solid tumors. " 05/01/2014 - "Patients with advanced solid tumors received escalating doses of MNRP1685A (7.5, 15, 24, and 36 mg/kg) with bevacizumab 15 mg/kg every 3 weeks in Arm A (n = 14). " 09/01/2012 - "To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a Phase I study to model with parallel linear and nonlinear clearances. " 05/01/2014 - "A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors."
2.	Urogenital Neoplasms 11/08/2023 - "Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection."
3.	Proteinuria 05/01/2014 - "However, a higher than expected rate of clinically significant proteinuria was observed that does not support further testing of MNRP1685A in combination with bevacizumab."
4.	COVID-19 11/08/2023 - "Specific inhibitors of the NRP1 antigen (pegaptanib, EG00229, or MNRP1685A) combined with other anti-SARS-CoV-2 strategies may aid in treating patients with lung and genitourinary cancers following SARS-CoV-2 infection."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	Neuropilin-1
3.	Paclitaxel (Taxol)
4.	Bevacizumab (Avastin)
5.	Antigens
6.	pegaptanib (Macugen)